Raymond James & Associates Ligand Pharmaceuticals Inc Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Raymond James & Associates holds 2,127 shares of LGND stock, worth $237,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,127
Holding current value
$237,288
% of portfolio
0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$82.7 - $110.11 $175,902 - $234,203
2,127 New
2,127 $213,000
Q1 2023

Apr 14, 2023
SELL
$65.67 - $77.08 $656 - $770
-10 Reduced 0.3%
3,334 $245,000
Q4 2022

Feb 08, 2023
SELL
$61.72 - $96.74 $1,419 - $2,225
-23 Reduced 0.68%
3,344 $223,000
Q3 2022

Oct 25, 2022
SELL
$0.01 - $107.56 $0 - $2,258
-21 Reduced 0.62%
3,367 $290,000
Q2 2022

Aug 12, 2022
SELL
$74.52 - $117.06 $8,197 - $12,876
-110 Reduced 3.14%
3,388 $302,000
Q3 2021

Nov 02, 2021
SELL
$102.33 - $144.73 $16,986 - $24,025
-166 Reduced 4.53%
3,498 $487,000
Q2 2021

Aug 11, 2021
SELL
$113.03 - $155.64 $1.53 Million - $2.11 Million
-13,573 Reduced 78.74%
3,664 $481,000
Q1 2021

May 14, 2021
SELL
$99.52 - $215.83 $890,604 - $1.93 Million
-8,949 Reduced 34.17%
17,237 $2.63 Million
Q4 2020

Feb 12, 2021
SELL
$80.55 - $106.05 $44,946 - $59,175
-558 Reduced 2.09%
26,186 $2.6 Million
Q3 2020

Nov 04, 2020
BUY
$89.56 - $126.72 $785,709 - $1.11 Million
8,773 Added 48.82%
26,744 $2.55 Million
Q2 2020

Jul 28, 2020
BUY
$68.28 - $123.65 $590,144 - $1.07 Million
8,643 Added 92.66%
17,971 $2.01 Million
Q1 2020

Apr 21, 2020
SELL
$63.37 - $107.88 $63,306 - $107,772
-999 Reduced 9.67%
9,328 $678,000
Q4 2019

Feb 12, 2020
SELL
$96.94 - $113.59 $135,134 - $158,344
-1,394 Reduced 11.89%
10,327 $1.08 Million
Q3 2019

Nov 07, 2019
SELL
$86.25 - $120.16 $56,321 - $78,464
-653 Reduced 5.28%
11,721 $1.17 Million
Q2 2019

Aug 06, 2019
BUY
$107.38 - $129.34 $60,025 - $72,301
559 Added 4.73%
12,374 $1.41 Million
Q1 2019

May 06, 2019
SELL
$105.93 - $142.47 $212,495 - $285,794
-2,006 Reduced 14.51%
11,815 $1.49 Million
Q4 2018

Feb 11, 2019
SELL
$128.36 - $272.13 $437,835 - $928,235
-3,411 Reduced 19.79%
13,821 $1.88 Million
Q3 2018

Nov 14, 2018
BUY
$211.18 - $274.49 $208,434 - $270,921
987 Added 6.08%
17,232 $4.73 Million
Q2 2018

Aug 14, 2018
BUY
$150.77 - $207.98 $47,794 - $65,929
317 Added 1.99%
16,245 $3.37 Million
Q1 2018

May 14, 2018
BUY
$138.63 - $182.62 $895,133 - $1.18 Million
6,457 Added 68.18%
15,928 $2.63 Million
Q4 2017

Feb 14, 2018
BUY
$128.36 - $147.04 $92,290 - $105,721
719 Added 8.22%
9,471 $1.3 Million
Q3 2017

Nov 13, 2017
BUY
$120.91 - $137.94 $10,640 - $12,138
88 Added 1.02%
8,752 $1.19 Million
Q2 2017

Aug 14, 2017
BUY
N/A
8,664
8,664 $1.05 Million

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email